Evaluating an Ebola and a Marburg Vaccine in Uganda

Inclusion Criteria: * Available for clinical follow-up through Week 104 * Willing to have photo taken for identification purposes * Willing to be taken home at enrollment visit and allow home visits if appointments are not kept * Completes an Assessment of Understanding (AoU) prior to enrollment by answering 9 out of 10 questions at least once in 3 attempts * In good general health without clinically significant medical history * Has a physical examination and laboratory results without clinically significant findings within the 28 days prior to enrollment * Female participants of reproductive potential must have a negative result on a human choriogonadotropin (β-HCG) pregnancy test * Female participants must either be incapable of becoming pregnant or agree to take appropriate precautions that pregnancy will not occur during the first 24 weeks of the study Exclusion Criteria: * Pregnant, breast-feeding, or planning to become pregnant during the first 24 weeks after enrollment * History of Ebola or Marburg virus exposure * Occupational health risk of exposure to the Ebola or Marburg virus known to be higher than that of the general population * Has received any of the following substances: * Investigational Ebola or Marburg vaccine in a prior clinical trial * Blood products within 120 days prior to HIV screening * Immunoglobulin within 60 days of prior to HIV screening * Live attenuated vaccines within 30 days prior to initial study vaccine administration * Inve…